PC
UTHR icon

Palo Capital’s United Therapeutics UTHR Stock Holding History

Palo Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,800
Closed -$402K – 200
2016
Q2 		$402K Buy
+3,800
New +$424K 0.14% 155

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Palo Capital's UTHR Position: Q3 2016 in Review

Palo Capital sold out of United Therapeutics (UTHR) in Q3 2016, closing a stake of 3,800 shares — an estimated $402K sold.

Palo Capital first reported a position in UTHR in Q2 2016 and held it in 1 quarter. The position peaked at $402K in Q2 2016. 394 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

  • Palo Capital reported no remaining United Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Palo Capital sold 3,800 United Therapeutics shares in Q3 2016, an estimated $402K.
  • Palo Capital first reported a position in United Therapeutics in Q2 2016 and held it in 1 quarter.
  • Palo Capital's United Therapeutics position peaked at $402K in Q2 2016.
  • 394 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on Palo Capital's 13F filing for Q3 2016, filed 20 Oct 2016.